IDEAYA Biosciences, Inc. Stock, NASDAQ:IDYA
7000 Shoreline Court, Suite 350, South San Francisco, California 94080
United States of America
Number of Employees: 47
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.